These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 30042327)

  • 21. Evidence for biofilms in onychomycosis.
    Gupta AK; Foley KA
    G Ital Dermatol Venereol; 2019 Feb; 154(1):50-55. PubMed ID: 29683287
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Onychomycosis: Diagnosis and management.
    Singal A; Khanna D
    Indian J Dermatol Venereol Leprol; 2011; 77(6):659-72. PubMed ID: 22016272
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pediatric Onychomycosis: The Emerging Role of Topical Therapy.
    Eichenfield LF; Friedlander SF
    J Drugs Dermatol; 2017 Feb; 16(2):105-109. PubMed ID: 28300851
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Dermatologist's Approach to Onychomycosis.
    Queller JN; Bhatia N
    J Fungi (Basel); 2015 Aug; 1(2):173-184. PubMed ID: 29376907
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemical and physical strategies in onychomycosis topical treatment: A review.
    Angelo T; Borgheti-Cardoso LN; Gelfuso GM; Taveira SF; Gratieri T
    Med Mycol; 2017 Jul; 55(5):461-475. PubMed ID: 27703019
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Opportunistic toenail onychomycosis. The fungal colonization of an available nail unit space by non-dermatophytes is produced by the trauma of the closed shoe by an asymmetric gait or other trauma. A plausible theory.
    Zaias N; Escovar SX; Rebell G
    J Eur Acad Dermatol Venereol; 2014 Aug; 28(8):1002-6. PubMed ID: 24708482
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efinaconazole topical solution, 10%: formulation development program of a new topical treatment of toenail onychomycosis.
    Bhatt V; Pillai R
    J Pharm Sci; 2015 Jul; 104(7):2177-82. PubMed ID: 25940933
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Update on the management of onychomycosis.
    Piraccini BM; Gianni C
    G Ital Dermatol Venereol; 2013 Dec; 148(6):633-8. PubMed ID: 24442043
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tavaborole in Difficult-to-Treat Onychomycosis Cases: A Post-hoc Assessment of Phase III Subjects.
    Aly R; Gupta AK; Winter T; Zane LT; Vlahovic T
    J Drugs Dermatol; 2017 Oct; 16(10):1016-1021. PubMed ID: 29036255
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Superficial white onychomycosis revisited.
    Baran R; Hay R; Perrin C
    J Eur Acad Dermatol Venereol; 2004 Sep; 18(5):569-71. PubMed ID: 15324395
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Onychomycosis therapy: past, present, future.
    Gupta AK; Uro M; Cooper EA
    J Drugs Dermatol; 2010 Sep; 9(9):1109-13. PubMed ID: 20865843
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Assessment of mycological and clinical factors on the course and results of treatment of mycotic infections in patients with recurrent onychomycosis].
    Ratajczak-Stefańska V
    Ann Acad Med Stetin; 2003; 49():161-71. PubMed ID: 15552846
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The future of onychomycosis therapy may involve a combination of approaches.
    Hay RJ
    Br J Dermatol; 2001 Oct; 145 Suppl 60():3-8. PubMed ID: 11777262
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ciclopirox nail lacquer: a brush with onychomycosis.
    Gupta AK
    Cutis; 2001 Aug; 68(2 Suppl):13-6. PubMed ID: 11665723
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Investigational drugs for onychomycosis.
    Gupta AK; Simpson FC
    Expert Opin Investig Drugs; 2014 Jan; 23(1):97-106. PubMed ID: 24070182
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy, safety and tolerability of an optimized avulsion technique with onyster® (40% urea ointment with plastic dressing) ointment compared to bifonazole-urea ointment for removal of the clinically infected nail in toenail onychomycosis: a randomized evaluator-blinded controlled study.
    Lahfa M; Bulai-Livideanu C; Baran R; Ortonne JP; Richert B; Tosti A; Piraccini BM; Szepietowski JC; Sibaud V; Coubetergues H; Voisard JJ; Paul C
    Dermatology; 2013; 226(1):5-12. PubMed ID: 23467055
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An investigation of how fungal infection influences drug penetration through onychomycosis patient's nail plates.
    McAuley WJ; Jones SA; Traynor MJ; Guesné S; Murdan S; Brown MB
    Eur J Pharm Biopharm; 2016 May; 102():178-84. PubMed ID: 26969264
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tavaborole (AN-2690) for the treatment of onychomycosis of the toenail in adults.
    Gupta AK; Daigle D
    Expert Rev Anti Infect Ther; 2014 Jul; 12(7):735-42. PubMed ID: 24894552
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Differential diagnosis of onychomycosis].
    Feuilhade de Chauvin M; Lacroix C
    Ann Dermatol Venereol; 2003 Dec; 130(12 Pt 2):1248-53. PubMed ID: 14743112
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A review of lasers and light for the treatment of onychomycosis.
    Ortiz AE; Avram MM; Wanner MA
    Lasers Surg Med; 2014 Feb; 46(2):117-24. PubMed ID: 24375507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.